Suppr超能文献

支持国际多实验室体内大鼠 Pig-a 检测验证试验的对乙酰氨基酚检测。

Testing of acetaminophen in support of the international multilaboratory in vivo rat Pig-a assay validation trial.

机构信息

Janssen Research & Development, Beerse, Antwerp, Belgium.

Janssen Research & Development, Spring House, Pennsylvania, USA.

出版信息

Environ Mol Mutagen. 2020 Jun;61(5):508-525. doi: 10.1002/em.22368. Epub 2020 Apr 15.

Abstract

Acetaminophen, a nonmutagenic compound as previously concluded from bacteria, in vitro mammalian cell, and in vivo transgenic rat assays, presented a good profile as a nonmutagenic reference compound for use in the international multilaboratory Pig-a assay validation. Acetaminophen was administered at 250, 500, 1,000, and 2,000 mg·kg ·day to male Sprague Dawley rats once daily in 3 studies (3 days, 2 weeks, and 1 month with a 1-month recovery group). The 3-Day and 1-Month Studies included assessments of the micronucleus endpoint in peripheral blood erythrocytes and the comet endpoint in liver cells and peripheral blood cells in addition to the Pig-a assay; appropriate positive controls were included for each assay. Within these studies, potential toxicity of acetaminophen was evaluated and confirmed by inclusion of liver damage biomarkers and histopathology. Blood was sampled pre-treatment and at multiple time points up to Day 57. Pig-a mutant frequencies were determined in total red blood cells (RBCs) and reticulocytes (RETs) as CD59-negative RBC and CD59-negative RET frequencies, respectively. No increases in DNA damage as indicated through Pig-a, micronucleus, or comet endpoints were seen in treated rats. All positive controls responded as appropriate. Data from this series of studies demonstrate that acetaminophen is not mutagenic in the rat Pig-a model. These data are consistent with multiple studies in other nonclinical models, which have shown that acetaminophen is not mutagenic. At 1,000 mg·kg ·day , Cmax values of acetaminophen on Day 28 were 153,600 ng/ml and 131,500 ng/ml after single and repeat dosing, respectively, which were multiples over that of clinical therapeutic exposures (2.6-6.1 fold for single doses of 4,000 mg and 1,000 mg, respectively, and 11.5 fold for multiple dose of 4,000 mg) (FDA 2002). Data generated were of high quality and valid for contribution to the international multilaboratory validation of the in vivo Rat Pig-a Mutation Assay.

摘要

对乙酰氨基酚先前在细菌、体外哺乳动物细胞和体内转基因大鼠检测中被判定为非诱变化合物,其作为非诱变参考化合物用于国际多实验室 Pig-a 检测验证具有良好的应用前景。在 3 项研究中,雄性 Sprague Dawley 大鼠每天经口给予对乙酰氨基酚 250、500、1000 和 2000mg·kg·day,每日 1 次,连续给药 3 天、2 周和 1 个月,其中 1 个月恢复期组(3 天、1 个月和 1 个月恢复期组)。3 天和 1 个月的研究除了进行 Pig-a 检测之外,还检测外周血红细胞的微核终点和肝细胞及外周血细胞的彗星终点;每个检测均包含适当的阳性对照。在这些研究中,通过包含肝损伤生物标志物和组织病理学,评估和证实了对乙酰氨基酚的潜在毒性。在预处理和多达第 57 天的多个时间点采集血液样本。通过 CD59 阴性 RBC 和 CD59 阴性 RET 频率分别确定总红细胞(RBC)和网织红细胞(RET)中的 Pig-a 突变频率。在给予对乙酰氨基酚的大鼠中,未观察到 DNA 损伤的增加,表明 Pig-a、微核或彗星终点无变化。所有阳性对照均有适当的反应。来自这一系列研究的数据表明,对乙酰氨基酚在大鼠 Pig-a 模型中没有致突变性。这些数据与其他非临床模型的多项研究一致,这些研究表明对乙酰氨基酚没有致突变性。在第 28 天,单次和重复给药后,对乙酰氨基酚的 Cmax 值分别为 153600ng/ml 和 131500ng/ml,分别为临床治疗暴露量的多倍(单次剂量分别为 4000mg 和 1000mg 的 2.6-6.1 倍,多次剂量为 4000mg 的 11.5 倍)(FDA 2002)。生成的数据质量很高,可用于为国际多实验室验证体内大鼠 Pig-a 突变检测做出贡献。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验